[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Texas Cardiac Arrhythmia Research Foundation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":98},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100657730","phase-3-optimal-anti-thrombotic-management-following-percutaneous-left-atrial-appendage-occlusion-100657730",false,"NCT07840365","Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage Occlusion","Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage Occlusion (INTEGRAL)","INTEGRAL","Inclusion Criteria:\n\n* • Men and women ≥18 years of age;\n\n  * Patients who underwent a clinically successful LAA closure procedure with a Watchman device (device implanted without procedural or bleeding complication) within a day or are scheduled to undergo the LAAO procedure\n  * Paroxysmal, persistent, or permanent AF patients irrespective of prior antithrombotic treatment are eligible for randomization,\n  * Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.\n\nExclusion Criteria:\n\n* Two or more clinical characteristics at baseline (age≥80 years, body weight ≤60 kg, serum creatinine ≥1.5 mg\u002FdL) requiring apixaban dosage adjustment;\n\n  * Mechanical heart valves or valvular disease requiring surgery or interventional procedure;\n  * Mandatory indication for dual antiplatelet therapy (e.g. recent stent) or single anti-platelet treatment (SAPT) (e.g. high coronary risk);\n  * Any contra-indication or known allergy to aspirin or clopidogrel or apixaban;\n  * Any mandatory indication for anticoagulation for a reason other than AF (e.g. Pulmonary embolism);\n  * Ongoing major bleeding or complicated or recent (\\\u003C72hours) major surgery;\n  * Recent myocardial infarction (\\\u003C6 weeks);\n  * Recent TE event (\\\u003C6 weeks)\n  * Recent Intracranial bleeding (\\\u003C 6 months);\n  * Prasugrel or ticagrelor concomitant use\n  * Participating in an investigational drug or another device trial within the previous 30 days;\n  * High likelihood of being unavailable for follow-up or psycho-social condition making study participation impractical;\n  * Pregnancy or within 48 hours post-partum or breast feeding women;\n  * Patient under legal protection.","ALL","18 Years",{"count":20,"type":21},234,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This randomized study was designed to compare two antithrombotic regimens (long-term half-dose apixaban vs long-term aspirin after 45-days of full-dose apixaban) after successful Watchman implantation.",[27],"Atrial Fibrillation (AF)",[29,30,31,32],"oral anticoagulation","Left atrial appendage occlusion","atrial fibrillation","Aspirin","RECRUITING","2026-09-29",{"date":36,"type":37},"2026-10-05","ACTUAL",{"date":39,"type":37},"2026-09-01",{"date":41,"type":21},"2029-09-30",{"name":43,"class":44},"Texas Cardiac Arrhythmia Research Foundation","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":45},"100478453","post-ablation-alcohol-impacts-arrhythmia-recurrence-quality-of-life-and-cognition-in-af-100478453","NCT05510167","Post-ablation Alcohol Impacts Arrhythmia Recurrence, Quality of Life and Cognition in AF","Impact of Post-ablation Alcohol Intake on Arrhythmia Recurrence, Quality of Life and Cognition in Patients With Atrial Fibrillation","PLATINUM","Inclusion Criteria:\n\n* AF patients that regularly consume \\>5 alcoholic drink (\\*12 g of pure alcohol\u002Fdrink)\u002Fweek\n* Paroxysmal or persistent AF\n* First catheter ablation History of alcohol-induced arrhythmia\n* Willing to sign the written informed consent\n\nExclusion Criteria:\n\n* Binge drinkers (alcohol dependence)\n* Non-drinkers\n* LVEF \\\u003C35%\n* Psychiatric conditions\n* MoCA score ≤ 17 on Montreal Cognitive Assessment (MoCA)\n* Patients with established dementia\n* Medically unstable patients (acute\u002Funstable or poorly controlled problems that would demand focused, relatively urgent or emergent medical attention)\n* Unwilling for alcohol-abstinence\n* Long-standing persistence AF\n* Patient under legal protection\n* Pregnancy","85 Years",{"count":56,"type":21},184,[58],"NA","Earlier studies have shown a dose-dependent relationship between alcohol intake and incident atrial fibrillation (AF) as well as a causal link with several risk factors for AF such as hypertension, obesity and sleep apnea. However, the effect of drinking (alcohol) on post-ablation outcome such as arrhythmia recurrence, quality of life (QoL) and cognitive function in AF patients is unclear. Therefore, we aim to find the answer for a very frequently asked question, \"is it safe to continue drinking alcohol (at the pre-ablation level) following catheter ablation OR should the intake be reduced for better outcome?\", in this randomized trial.",[61],"Atrial Fibrillation",[63,64,65,66],"Alcohol","AF","catheter ablation","recurrence","2026-09-09",{"date":69,"type":37},"2026-09-14",{"date":71,"type":37},"2022-08-22",{"date":73,"type":21},"2027-08",{"name":43,"class":44},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100583638","safety-and-efficacy-of-pulmonary-vein-isolation-using-pulsed-field-ablation-pfa-combined-with-either-pfa-based-left-atrial-posterior-wall-isolation-or-vein-of-marshall-ethanol-ablation-in-patients-with-persistent-atrial-fibrillation-100583638","NCT06878924","Safety and Efficacy of Pulmonary Vein Isolation Using Pulsed-field Ablation (PFA) Combined with Either PFA-based Left Atrial Posterior Wall Isolation or Vein of Marshall Ethanol Ablation in Patients with Persistent Atrial Fibrillation","SAVIOR","Inclusion Criteria:\n\n* Symptomatic persistent AF; 1st or redo ablation with PVI-only in the earlier procedure\n* Willing to provide informed consent\n* Age: 18-85 years\n\nExclusion Criteria:\n\n* • Previous PWI or VoM ablation procedure\n\n  * Left ventricular ejection fraction \\\u003C40%\n  * Left atrial thrombus\n  * Myocardial infarction within last 60 days\n  * Cardiac surgery in the last 6 months\n  * Advanced renal failure\n  * Life expectancy \\\u003C1 year\n  * Pregnant women\n  * Unable or unwilling to provide informed consent",{"count":83,"type":21},162,"OBSERVATIONAL","This study is designed to directly compare the safety and efficacy of PFA-based PVI+PWI vs PFA-based PVI+ VoM alcohol ablation in patients with Persistent AF.",[27],[88],"Persistent AF","NOT_YET_RECRUITING","2025-03-10",{"date":92,"type":37},"2025-03-17",{"date":94,"type":21},"2025-05",{"date":96,"type":21},"2027-12",{"name":43,"class":44},""]